- Product NameRosiglitazone
- Brief DescriptionInhibitors
- Purification98.00%
- Biological ActivityRosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPAR?. Rosiglitazone is a selective ligand of PPAR?, and has no PPAR?-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NF?B) levels fall and inhibitor (I?B) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.
- Target NamePPAR agonist
- CAS No. 122320-73-4
- Calculated MW 357.43
- Formulation C18H19N3O3S
- Storage 3 years -20˚C powder;2 years -80˚C in solvent;
